Chondroitin sulfate effect on induced arthritis in rats

Osteoarthritis and Cartilage

Volumn 19, Issue 11, 2011, Pages 1373-1379

  Bauerova, K ^a   Ponist, S ^a   Kuncirova, V ^a   Mihalova, D ^a   Paulovicova, E ^b   Volpi, N ^c  

^a INSTITUTE OF EXPERIMENTAL PHARMACOLOGY AND TOXICOLOGY   (Slovakia)

^b INSTITUTE OF CHEMISTRY   (Slovakia)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Adjuvant arthritis; Chondroitin sulfate; Glycosaminoglycans; Oral route; Osteoarthritis; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; CHONDROITIN SULFATE; FREUND ADJUVANT; GAMMA GLUTAMYLTRANSFERASE;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CHRONIC INFLAMMATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFECT; ENZYME ACTIVITY; MALE; MYCOBACTERIUM BUTYRICUM; NEUTROPHIL; NONHUMAN; OXIDATIVE STRESS; PHAGOCYTOSIS; PRIORITY JOURNAL; RAT; RESPIRATORY BURST;

ANIMALS; ANTIOXIDANTS; ARTHRITIS, EXPERIMENTAL; C-REACTIVE PROTEIN; CHONDROITIN SULFATES; CYTOKINES; DISEASE MODELS, ANIMAL; GAMMA-GLUTAMYLTRANSFERASE; HINDLIMB; MALE; NEUTROPHILS; OXIDATIVE STRESS; PHAGOCYTES; RATS; RATS, INBRED LEW;

EID: 80053638196     PISSN: 10634584     EISSN: 15229653     Source Type: Journal    
DOI: 10.1016/j.joca.2011.08.006     Document Type: Article

References (34)

1. Chondroitin Sulfate: Structure, Role and Pharmacological Activity 2006, Academic Press, Amsterdam. N. Volpi (Ed.).
2. Volpi N. Analytical aspects of pharmaceutical grade chondroitin sulfates. J Pharm Sci 2007, 96:3168-3180.
3. Volpi N. Quality of different chondroitin sulfate preparations in relation to their therapeutic activity. J Pharm Pharmacol 2009, 61:1271-1280.
4. Uebelhart D. Clinical review of chondroitin sulfate in osteoarthritis. Osteoarthritis Cartilage 2008, 16:S19-S21.
5. Jordan K.M., Arden N.K., Doherty M., Bannwarth B., Bijlsma J.W., Dieppe P., et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003, 62:1145-1155.
6. Zhang W., Doherty M., Leeb B.F., Alekseeva L., Arden N.K., Bijlsma J.W., et al. EULAR evidence based recommendations for the management of hand osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007, 66:377-388.
7. Reginster J.Y., Heraud F., Zegels B., Bruyere O. Symptom and structure modifying properties of chondroitin sulfate in osteoarthritis. Mini Rev Med Chem 2007, 7:1051-1061.
8. Kahan A., Uebelhart D., De Vathaire F., Delmas P.D., Reginster J.Y. Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2009, 60:524-533.
9. Omata T., Itokazu Y., Inoue N., Segawa Y. Effects of chondroitin sulfate-C on articular cartilage destruction in murine collagen-induced arthritis. Arzneimittelforschung 2000, 50:148-153.
10. Cho S.Y., Sim J.S., Jeong C.S., Chang S.Y., Choi D.W., Toida T., et al. Effects of low molecular weight chondroitin sulfate on type II collagen-induced arthritis in DBA/1J mice. Biol Pharm Bull 2004, 27:47-51.
11. Jin C.-H., Yang U., Kim S.-H., Ryu J.-W., Lee J.-C., Lee D.-S., et al. The protective effect of chondroitin from Raja kenojei cartilage on collagen-induced arthritis in DBA/1J mice. Food Sci Biotechnol 2007, 16:594-599.
12. Sakai S., Akiyama H., Sato Y., Yoshioka Y., Linhardt R.J., Goda Y., et al. Chondroitin sulfate intake inhibits the IgE-mediated allergic response by down-regulating Th2 responses in mice. J Biol Chem 2006, 281:19872-19880.
13. Uebelhart D., Thonar E.J., Zhang J., Williams J.M. Protective effect of exogenous chondroitin 4,6-sulfate in the acute degradation of articular cartilage in the rabbit. Osteoarthritis Cartilage 1998, (6 Suppl A):6-13.
14. Herrero-Beaumont G., Marcos M.E., Sánchez-Pernaute O., Granados R., Ortega L., Montell E., et al. Effect of chondroitin sulphate in a rabbit model of atherosclerosis aggravated by chronic arthritis. Br J Pharmacol 2008, 154:843-851.
15. Bendele A., McComb J., Gould T., McAbee T., Sennello G., Chlipala E., et al. Animal models of arthritis: relevance to human disease. Toxicol Pathol 1999, 27:134-142.
16. Rovensky J., Stančikova M., Švik K., Bauerova K., Jurčovičova J. The effects of beta glucan isolated from Pleurotus ostreatus on methotrexate treatment in rats with adjuvant arthritis. Rheumatol Int 2011, 31:507-511.
17. Bauerova K., Poništ S., Mihalova D., Drafi F., Kuncirova V. Utilization of adjuvant arthritis model for evaluation of new approaches in rheumatoid arthritis therapy focused on regulation of immune processes and oxidative stress. Interdisc Toxicol 2011, 4:101-107.
18. Miller N.J., Rice-Evans C., Davies M.J., Gopinathan V., Milner A. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci 1993, 84:407-412.
19. Orlowski M., Meister A. The gamma-glutamyl cycle: a possible transport system for amino acids. Proc Natl Acad Sci USA 1970, 67:1248-1255.
20. Ondrejickova O., Ziegelhoeffer A., Gabauer I., Sotnikova R., Styk J., Gibala P., et al. Evaluation of ischemia-reperfusion injury by malondialdehyde, glutathione and gamma-glutamyl transpeptidase: lack of specific local effects in diverse parts of the dog heart following acute coronary occlusion. Cardioscience 1993, 4:225-230.
21. Kronek J., Luston J., Kronekova Z., Paulovicova E., Farkas P., Petrencikova N., et al. Synthesis and bioimmunological efficiency of poly(2-oxazolines) containing a free amino group. J Mater Sci Mater Med 2010, 21:879-886.
22. Kannan K., Ortmann R.A., Kimpel D. Animal models of rheumatoid arthritis and their relevance to human disease. Pathophysiology 2005, 12:167-181.
23. Ishizuka Y., Moriwaki S., Kawahara-Hanaoka M., Uemura Y., Serizawa I., Miyauchi M., et al. Treatment with anti-gamma-glutamyl transpeptidase antibody attenuates osteolysis in collagen-induced arthritis mice. J Bone Miner Res 2007, 22:1933-1942.
24. Burmester G.R., Stuhlmuller B., Keyszer G., Kinne R.W. Mononuclear phagocytes and rheumatoid synovitis. Mastermind or workhorse in arthritis?. Arthritis Rheum 1997, 40:5-18.
25. Hussein M.R., Fathi N.A., El-Din A.M., Hassan H.I., Abdullah F., Al-Hakeem E., et al. Alterations of the CD4+, CD8+ T cell subsets, interleukins-1β, IL-10, IL-17, tumor necrosis factor-α and soluble intercellular adhesion molecule-1 in rheumatoid arthritis and osteoarthritis: preliminary observations. Pathol Oncol Res 2008, 14:321-328.
26. Altman R.D. Pharmacological therapies for osteoarthritis of the hand: a review of the evidence. Drugs Aging 2010, 27:729-745.
27. Martínez-Calatrava M.J., Largo R., Herrero-Beaumont G. Improvement of experimental accelerated atherosclerosis by chondroitin sulphate. Osteoarthritis Cartilage 2010, (18 Suppl 1):S12-S16.
28. Hochberg M.C. Structure-modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trials of 2-year duration. Osteoarthritis Cartilage 2010, (18 Suppl 1):S28-S31.
29. Chu Z.L., McKinsey T.A., Liu L., Gentry J.J., Malim M.H., Ballard D.W. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc Natl Acad Sci USA 1997, 94:10057-10062.
30. Karin M., Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 2002, 3:221-227.
31. Vallières M., du Souich P. Modulation of inflammation by chondroitin sulfate. Osteoarthritis Cartilage 2010, (18 Suppl 1):S1-S6.
32. Egea J., García A.G., Verges J., Montell E., López M.G. Antioxidant, antiinflammatory and neuroprotective actions of chondroitin sulfate and proteoglycans. Osteoarthritis Cartilage 2010, (18 Suppl 1):S24-S27.
33. Wildi L.M., Raynauld J.P., Martel-Pelletier J., Beaulieu A., Bessette L., Morin F., et al. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI. Ann Rheum Dis 2011.
34. Henrotin Y., Mathy M., Sanchez Ch, Lambert C. Chondroitin sulfate in the treatment of osteoarthritis: from in vitro studies to clinical recommendations. Ther Adv Musculoskel Dis 2010, 2:335-348.